Phaseline

Companies › Mendus

Mendus: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
vididencel
autologous dendritic cell vaccine
–Phase 1CML (Chronic Myelogenous Leukemia)Sep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07651878vididencelPhase 1CML (Chronic Myelogenous Leukemia)OncologySep 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.